Patents by Inventor Gustavo A. Fischbein
Gustavo A. Fischbein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10172800Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: August 10, 2017Date of Patent: January 8, 2019Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
-
Publication number: 20180200215Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: March 13, 2018Publication date: July 19, 2018Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20180200214Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: March 13, 2018Publication date: July 19, 2018Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20170354625Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: August 18, 2017Publication date: December 14, 2017Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Patent number: 9833412Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: GrantFiled: February 24, 2014Date of Patent: December 5, 2017Assignee: Osmotica Kereskedelmi es Szolgaltato KFTInventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Publication number: 20170340570Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: August 10, 2017Publication date: November 30, 2017Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
-
Publication number: 20170340592Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: August 10, 2017Publication date: November 30, 2017Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Patent number: 9801841Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: April 20, 2017Date of Patent: October 31, 2017Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Publication number: 20170216236Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: April 20, 2017Publication date: August 3, 2017Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Patent number: 9655858Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: May 4, 2016Date of Patent: May 23, 2017Assignee: Osmotica Kereskedelmi es Szolgaltato KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 9585843Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: April 19, 2016Date of Patent: March 7, 2017Assignee: Osmotica Kereskedelmi es Szoloaltato KftInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 9579289Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: February 19, 2016Date of Patent: February 28, 2017Assignee: Osmotica Kereskedelmi es Szolgaltato KftInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Publication number: 20160263043Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: February 19, 2016Publication date: September 15, 2016Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20160243072Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: May 4, 2016Publication date: August 25, 2016Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20160243067Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: April 19, 2016Publication date: August 25, 2016Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20140302141Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: February 24, 2014Publication date: October 9, 2014Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: FERNANDO G. TONEGUZZO, GLENN A. MEYER, Marcelo A. RICCI, Marcelo A. COPPARI, ANA C. PASTINI, GUSTAVO A. FISCHBEIN
-
Patent number: 8685451Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: GrantFiled: June 18, 2008Date of Patent: April 1, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Patent number: 8637080Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: GrantFiled: June 25, 2008Date of Patent: January 28, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Publication number: 20090004229Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: OSMOTICA COSTA RICA SOCIEDAD ANONIMAInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Publication number: 20080299197Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: June 18, 2008Publication date: December 4, 2008Applicant: OSMOTICA CORP.Inventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein